- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Revisiting IDO and its value as a predictive marker for anti-PD-1 resistance ; volume:17 ; number:1 ; day:18 ; month:1 ; year:2019 ; pages:1-2 ; date:12.2019
Journal of translational medicine ; 17, Heft 1 (18.1.2019), 1-2, 12.2019
- Creator
-
Moon, Peter Kim
Tran, Stephanie
Minhas, Paras Singh
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-019-1784-8
- URN
-
urn:nbn:de:101:1-2019022022122164711254
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Moon, Peter Kim
- Tran, Stephanie
- Minhas, Paras Singh
- SpringerLink (Online service)
Other Objects (12)
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Idő kérdése
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy
Idő kérdése
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Management of Localized Melanoma in the Anti-PD-1 Era
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
Changes in peripheral blood PD-1 receptor expression under anti-PD-1 Immune Checkpoint Therapy